
AxoGen (AXGN) Stock Forecast & Price Target
AxoGen (AXGN) Analyst Ratings
Bulls say
Axogen is well positioned in the market with its Avance Nerve Graft approved as a biologic, strong cash position, and expected 20% revenue growth for FY2026. The company's valuation is supported by a comparable universe analysis, with projected sales per share of $5.31 and net cash of $1.95 per share resulting in a price objective of $50. Despite potential risks such as government regulation risk and competition from larger medical device companies, Axogen has strong growth potential and its differentiated products make it a promising investment opportunity.
Bears say
Axogen is in the early stages of refining its techniques to enter the $754 million TAM in prostate treatment, with a substantive readout expected in 3Q26; their balance sheet is in good shape with $103.6 million in cash and no debt obligations, and management plans to use their positive free cash flow for continued infrastructure investment and opportunistic M&A in nerve repair adjacencies. Their most recent reported total of $16,611 in stock-based compensation has been normalized to $7,236, which will improve the accuracy of estimates for future quarters and adjust operating expenses as well.
This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.
AxoGen (AXGN) Analyst Forecast & Price Prediction
Start investing in AxoGen (AXGN)
Order type
Buy in
Order amount
Est. shares
0 shares